FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3109308944> ?p ?o ?g. }

• W3109308944 endingPage "397" @default.
• W3109308944 startingPage "389" @default.
• W3109308944 abstract "TGFβ is a pleiotropic cytokine with immunosuppressive activity. In preclinical models, blockade of TGFβ enhances the activity of radiation and invokes T-cell antitumor immunity. Here, we combined galunisertib, an oral TGFβ inhibitor, with stereotactic body radiotherapy (SBRT) in patients with advanced hepatocellular carcinoma (HCC) and assessed safety, efficacy, and immunologic correlatives. Patients (n = 15) with advanced HCC who progressed on, were intolerant of, or refused sorafenib were treated with galunisertib (150 mg orally twice a day) on days 1 to 14 of each 28-day cycle. A single dose of SBRT (18-Gy) was delivered between days 15 to 28 of cycle 1. Site of index lesions treated with SBRT included liver (9 patients), lymph node (4 patients), and lung (2 patients). Blood for high-dimensional single cell profiling was collected. The most common treatment-related adverse events were fatigue (53%), abdominal pain (46.6%), nausea (40%), and increased alkaline phosphatase (40%). There were two instances of grade 2 alkaline phosphatase increase and two instances of grade 2 bilirubin increase. One patient developed grade 3 achalasia, possibly related to treatment. Two patients achieved a partial response. Treatment with galunisertib was associated with a decrease in the frequency of activated T regulatory cells in the blood. Distinct peripheral blood leukocyte populations detected at baseline distinguished progressors from nonprogressors. Nonprogressors also had increased CD8+PD-1+TIGIT+ T cells in the blood after treatment. We found galunisertib combined with SBRT to be well tolerated and associated with antitumor activity in patients with HCC. Pre- and posttreatment immune profiling of the blood was able to distinguish patients with progression versus nonprogression." @default.
• W3109308944 created "2020-12-07" @default.
• W3109308944 creator A5000177032 @default.
• W3109308944 creator A5013636222 @default.
• W3109308944 creator A5014753848 @default.
• W3109308944 creator A5017772864 @default.
• W3109308944 creator A5025028905 @default.
• W3109308944 creator A5027472767 @default.
• W3109308944 creator A5029750461 @default.
• W3109308944 creator A5040750947 @default.
• W3109308944 creator A5042763431 @default.
• W3109308944 creator A5043577990 @default.
• W3109308944 creator A5052816083 @default.
• W3109308944 creator A5061377078 @default.
• W3109308944 creator A5071139217 @default.
• W3109308944 creator A5075482801 @default.
• W3109308944 creator A5079376334 @default.
• W3109308944 creator A5083527157 @default.
• W3109308944 creator A5091627516 @default.
• W3109308944 date "2021-02-01" @default.
• W3109308944 modified "2023-10-15" @default.
• W3109308944 title "A Pilot Study of Galunisertib plus Stereotactic Body Radiotherapy in Patients with Advanced Hepatocellular Carcinoma" @default.
• W3109308944 cites W1487631743 @default.
• W3109308944 cites W1631320694 @default.
• W3109308944 cites W1975605578 @default.
• W3109308944 cites W1980780108 @default.
• W3109308944 cites W1987165863 @default.
• W3109308944 cites W2032166347 @default.
• W3109308944 cites W2039123767 @default.
• W3109308944 cites W2045963664 @default.
• W3109308944 cites W2055061339 @default.
• W3109308944 cites W2070269722 @default.
• W3109308944 cites W2086454079 @default.
• W3109308944 cites W2097811455 @default.
• W3109308944 cites W2153060237 @default.
• W3109308944 cites W2185023695 @default.
• W3109308944 cites W2194546364 @default.
• W3109308944 cites W2345250542 @default.
• W3109308944 cites W2584495362 @default.
• W3109308944 cites W2606367731 @default.
• W3109308944 cites W2606705797 @default.
• W3109308944 cites W2777478371 @default.
• W3109308944 cites W2789720205 @default.
• W3109308944 cites W2811128944 @default.
• W3109308944 cites W2912648593 @default.
• W3109308944 cites W2916647762 @default.
• W3109308944 cites W2937730750 @default.
• W3109308944 cites W2947829857 @default.
• W3109308944 cites W2961711453 @default.
• W3109308944 cites W2962221292 @default.
• W3109308944 cites W2963299585 @default.
• W3109308944 cites W2970741715 @default.
• W3109308944 cites W2986357309 @default.
• W3109308944 cites W3011153080 @default.
• W3109308944 cites W3023772547 @default.
• W3109308944 cites W3025022288 @default.
• W3109308944 cites W4232620598 @default.
• W3109308944 doi "https://doi.org/10.1158/1535-7163.mct-20-0632" @default.
• W3109308944 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7867621" @default.
• W3109308944 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33268571" @default.
• W3109308944 hasPublicationYear "2021" @default.
• W3109308944 type Work @default.
• W3109308944 sameAs 3109308944 @default.
• W3109308944 citedByCount "7" @default.
• W3109308944 countsByYear W31093089442021 @default.
• W3109308944 countsByYear W31093089442022 @default.
• W3109308944 countsByYear W31093089442023 @default.
• W3109308944 crossrefType "journal-article" @default.
• W3109308944 hasAuthorship W3109308944A5000177032 @default.
• W3109308944 hasAuthorship W3109308944A5013636222 @default.
• W3109308944 hasAuthorship W3109308944A5014753848 @default.
• W3109308944 hasAuthorship W3109308944A5017772864 @default.
• W3109308944 hasAuthorship W3109308944A5025028905 @default.
• W3109308944 hasAuthorship W3109308944A5027472767 @default.
• W3109308944 hasAuthorship W3109308944A5029750461 @default.
• W3109308944 hasAuthorship W3109308944A5040750947 @default.
• W3109308944 hasAuthorship W3109308944A5042763431 @default.
• W3109308944 hasAuthorship W3109308944A5043577990 @default.
• W3109308944 hasAuthorship W3109308944A5052816083 @default.
• W3109308944 hasAuthorship W3109308944A5061377078 @default.
• W3109308944 hasAuthorship W3109308944A5071139217 @default.
• W3109308944 hasAuthorship W3109308944A5075482801 @default.
• W3109308944 hasAuthorship W3109308944A5079376334 @default.
• W3109308944 hasAuthorship W3109308944A5083527157 @default.
• W3109308944 hasAuthorship W3109308944A5091627516 @default.
• W3109308944 hasBestOaLocation W31093089441 @default.
• W3109308944 hasConcept C126322002 @default.
• W3109308944 hasConcept C143998085 @default.
• W3109308944 hasConcept C197934379 @default.
• W3109308944 hasConcept C2778019345 @default.
• W3109308944 hasConcept C2780580376 @default.
• W3109308944 hasConcept C71924100 @default.
• W3109308944 hasConcept C90924648 @default.
• W3109308944 hasConceptScore W3109308944C126322002 @default.
• W3109308944 hasConceptScore W3109308944C143998085 @default.
• W3109308944 hasConceptScore W3109308944C197934379 @default.
• W3109308944 hasConceptScore W3109308944C2778019345 @default.
• W3109308944 hasConceptScore W3109308944C2780580376 @default.

• next